Guillain-Barré Syndrome after Hematopoietic Transplantation

Christianne Tolêdo de Souza Leal*, Marcelo Maroco Cruzeiro and Abrahão Elias Hallack Neto

Department of Internal Medicine, Federal University of Juiz de Fora, Brazil

^*Correspondance to: Christianne Tolêdo de Souza Leal 

 PDF  Full Text Case Report | Open Access

Abstract:

The Hematology Service at the University Hospital of Federal University of Juiz de Fora (HUUFJF)/ Brazil carried out a research project focused on assessing the toxicity and effectiveness of progressive Lomustine doses in association with Etoposide and Cyclophosphamide in the Autologous Hematopoietic Stem Cell Transplantation (AHSCT) conditioning regimen adopted for lymphoma patients. During the follow-up, a 31-year-old woman belonging to the 400 mg/m2 Lomustine cohort evolved with neuromuscular complications 6 months after AHSCT. Initially, she experienced diffuse pain, mainly proximal weakness in the lower limbs; however, it got worse 10 days after vaccine protocol application. She evolved with rapidly ascending motor worsening, decreased ability to walk, foot paresthesia, binocular diplopia, areflexia, bulbar and dysautonomic symptoms such as sweating, tachycardia and postural hypotension. She experienced syncope episodes 72 h before being referred to intensive care unit at HU-UFJF.

Keywords:

Cite the Article:

de Souza Leal CT, Cruzeiro MM, Hallack Neto AE. Guillain-Barré Syndrome after Hematopoietic Transplantation. Ann Clin Case Rep. 2022; 7: 2161..